register

News & Trends - MedTech & Diagnostics

Highly targeted therapy for Australian prostate cancer patients

Health Industry Hub | July 23, 2020 |

MedTech News: A NSW prostate cancer patient is the first to receive highly targeted cancer therapy using an MR Linac at the GenesisCare oncology centre within St Vincent’s Hospital in Darlinghurst.

This is the first centre in NSW and the second in Australia to offer treatment using the Elekta Unity MR-Linac. It combines a state-of-the-art MRI imaging scanner and a linear accelerator so treatment specialists can see tumours and adapt treatment in real time.

The MR Linac is available to treat patients with prostate or oligometastatic cancer, with new capabilities to treat additional tumour types to be introduced in the future.

The MR-Linac system is the latest advancement in stereotactic body radiation therapy (SBRT), a non-invasive type of radiation therapy which involves delivering radiation from a source outside the body. While it is generally administered daily for several weeks (between 20-40 sessions in
total), SRBT allows clinicians to deliver a higher dose of radiation across five or less daily sessions.

Former teacher and high school principal, Rod Brooks, 68yo, was diagnosed with prostate cancer in May 2020 after a blood test returned elevated prostate specific antigen (PSA) levels.

This is the second time Rod was told he had cancer, having been diagnosed and treated for bowel cancer in 2007.

“I get regular checkups and blood tests to check my bowel cancer is still in remission, so you can imagine my surprise when the doctor told me that I had cancer again.

“Prostate cancer surgery wasn’t really an option for me after my bowel cancer operation, so I was grateful there were non-invasive treatments that would allow me to keep active and out of hospital,” said Mr Brooks.

Shortly after his bowel cancer diagnosis, Rod became the primary carer for his wife, Kerry, who had multiple sclerosis (MS), a degenerative disease of the brain and spinal cord for which there is no cure. She passed away in 2018.

“I have survived bowel cancer and the invasive treatments that went with it, and then lost my wife two years ago. When I was diagnosed with prostate cancer in May, I thought ‘oh no, not again, what else can happen to me?’ but you just have to stay positive.

“Part of staying positive is keeping active and doing the things you love – for me that’s competitive sailing and playing golf with friends. Continuing these throughout my treatment is really important to me,” said Mr Brooks.

GenesisCare MR-Linac Lead Radiation Oncologist, Dr Jeremy de Leon, said “Many tumours are located in organs that move during or between radiation treatment sessions. Tumours can also be located near sensitive organs or tissues, such as the bladder or bowel, so we need to be able to precisely deliver radiation within millimetres, so we target the tumour and not other organs.

“The MR-Linac enables clinicians to visualise the tumour during treatment and adapt to changes in tumour size and location. This allows us to target cancer more precisely and deliver highly personalised therapy each time a patient is treated,”10-12 said Dr de Leon.

“This adaptive patient care in radiation therapy helps to minimise exposure to surrounding healthy tissue and may result in reduced treatment-related side effects, less treatment sessions and fewer visits to the hospital, thereby reducing the overall burden on patients.”

Cancer is a major cause of illness in Australia, and prostate cancer is the nation’s most commonly diagnosed cancer in men, with almost 20,000 men diagnosed with the disease last year alone. It is also Australia’s third most common cause of cancer death (after lung and colorectal cancer), claiming the lives of more than 3,300 Australian men each year.

GenesisCare Chief Executive Officer, Dan Collins, said “More than ever in these challenging times, we want to ensure that cancer patients across New South Wales and right around the world receive the right care when it’s needed. This is why we are continuing our investment in the latest technology through our partnership with Elekta.

“The Elekta Unity is a significant step forward for patients with complex cancers. It will allow us to expand treatment options for many people living with cancer across the state. Our wonderful physicians and team members at our centre at St Vincent’s in Sydney are passionate innovators, and this system will enable them to realise outcomes for patients beyond what was possible before.

We will also foster new research, techniques and innovation based around the huge potential of imaged guided radiation therapy,” said Mr Collins. Elekta Acting President and Chief Financial Officer, Gustaf Salford said

“With a shared focus on patient-centric care, we are uniting with GenesisCare to ensure treating clinicians can access the latest innovations in adaptive radiation therapy technology for their patients.”


News & Trends - Pharmaceuticals

Manoj Saxena - Bayer

Breaking the mold: Bayer GM on the future of pharma workplaces – Reimagining Healthcare Senior Leadership Series

Health Industry Hub | July 18, 2024 |

In the latest episode of the Reimagining Healthcare senior leadership series, Manoj Saxena, General Manager Pharmaceuticals ANZ at Bayer voiced […]

More


News & Trends - Pharmaceuticals

Matt Zeller, Country President of Novartis ANZ

Novartis Country President talks essentials in shaping the future of health policy: Reimagining Healthcare senior leadership series

Health Industry Hub | July 18, 2024 |

In this episode of the Reimagining Healthcare senior leadership series, Matt Zeller, Country President of Novartis ANZ, explores how health […]

More


Medical

First guidelines to stamp out rising scientific integrity issues in medical journals

First guidelines to stamp out rising scientific integrity issues in medical journals

Health Industry Hub | July 18, 2024 |

The number of retractions issued for scientific research articles in 2023 exceeded 10,000 – smashing annual records. To date, publishers […]

More


News & Trends - Pharmaceuticals

Gilead secures MSAC nod for CAR-T therapy

Gilead secures MSAC nod for CAR-T therapy

Health Industry Hub | July 18, 2024 |

Pharma News: Gilead Sciences welcomes the Medical Services Advisory Committee (MSAC) recommendation for public funding of Yescarta (axicabtagene ciloleucel) as […]

More


This content is copyright protected. Please subscribe to gain access.